Mangalam Drugs And Organics Limited

Mangalam Drugs And Organics Limited (MANGALAM) is a micro-cap Healthcare company valued at ₹49 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Mangalam Drugs And Organics Limited last traded at ₹31, modestly down 1.96% on the day.

Recent developments

On 2026-06-30, the company reported a net loss of ₹44 crore for the fiscal year ending March 2026, marking a swing from a net profit of ₹7 crore in the previous year. Promoter holding remained at 35.65% as of June 2026, while foreign institutional holding decreased by 0.21 percentage points to 0.11%.

Financial performance

The company's business is deteriorating, with annual revenue falling 27.0% and annual net profit swinging to a loss of ₹44 crore. The latest quarter shows a slight improvement, with net loss narrowing from ₹14 crore to ₹8 crore, but revenue remained flat compared to the same quarter a year earlier.

Valuation multiples

A price-to-earnings ratio is not meaningful here because the company is loss-making; the stock trades at 0.45 times book value.

Things to watch

The company is currently in a net loss, with a net profit margin of -19.1% and return on equity at 0.0%. The return on capital employed is negative at -15.5%, and the debt to equity ratio is 1.02, indicating financial strain. The stock is 60.6% below its 52-week high.

Where it stands

Mangalam Drug & Chem Ltd ended its latest fiscal year with a net loss of ₹44 crore, a sharp decline from a net profit of ₹7 crore. The latest quarter saw a narrowing net loss, but revenue remained flat. The stock is significantly below its 52-week high, and the company's financial metrics show continued pressure.

Summarised by DocStoX's model on 2026-10-04 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.